Pipeline
ZyVersa's mission is to develop novel, first-in-class drugs that optimize health outcomes and improve patients' quality of life. Our evolving product pipeline is targeted at anti-inflammatory and renal diseases.
Pipeline
Our lead anti-inflammatory drug candidate is Inflammasome ASC Inhibitor IC 100, targeting the innate immune system. IC 100 inhibits intracellular ASC to block formation of multiple types of inflammasomes and attenuate intracellular initiation of the inflammatory cascade. It also inhibits intra-and extracellular ASC specks to attenuate perpetuation of systemic inflammation and its spread to other tissues and organs. The lead Indication for IC 100 is obesity and its associated metabolic complications. IC 100 has potential for treatment of numerous inflammatory conditions, including CNS conditions, such as Parkinson’s and Alzheimer’s disease, and non-CNS conditions, such as atherosclerosis.
Our lead renal candidate is Cholesterol Efflux MediatorTM VAR 200 (active ingredient 2-hydroxypropyl-beta-cyclodextrin or 2HPβCD). VAR 200 was developed to mediate removal of excess cholesterol and lipids that damage the kidneys’ filtration system (renal glomeruli podocytes). Based on preclinical studies, by reducing excess cholesterol and lipids, VAR 200 protects against injury to the kidneys’ filtration system and reduces protein in the urine (proteinuria) that can lead to end stage kidney disease.
A Phase 2a pilot study with VAR 200 in patients with diabetic kidney disease will be initiated in the upcoming weeks. VAR 200 has potential for treatment of orphan indications, focal segmental glomerulosclerosis (FSGS) and Alport syndrome, in addition to diabetic kidney disease.